AbbVie (ABBV) stock
Health Care · Biotechnology
AbbVie (ABBV) is a Biotechnology company in the Health Care sector, headquartered in North Chicago, Illinois. As of October 23, 2026, ABBV closed at $285.64, a market capitalization of $504.76 billion, the 20th largest company in the S&P 500. Over the last twelve months it generated $64.39 billion in revenue (+10% year over year) and $18.21 billion in free cash flow. The stock trades at 80.7x trailing earnings and 17.6x forward earnings.
- 1-year total return: +28.9% (dividends reinvested)
- 5-year return: +25.6% a year
- 52-week range: $190.75 – $291.40
- Gross margin 72.8%, operating margin 40.0%
- Dividend yield: 2.42%, 12 straight years of increases
- FI Handbook report card: B across 9 metrics
- 3rd largest of 60 Health Care stocks in the S&P 500
ABBV price chart
1Y price change: +25.1% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| ABBV | +8.4% | +28.8% | +28.9% | +29.7% | +25.6% | +21.6% | +21.1% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 2013.
ABBV key statistics
- Market cap
- $504.8B
- #20 in S&P 500
- P/E (TTM)
- 80.7x
- Forward P/E
- 17.6x
- EPS (TTM)
- $3.54
- Revenue (TTM)
- $64.4B
- +10%
- Free cash flow
- $18.2B
- Gross margin
- 72.8%
- Operating margin
- 40.0%
- Return on equity
- —
- Dividend yield
- 2.42%
- 52-week range
- $190.75 – $291.40
- Beta
- 0.23
- Price / sales
- 7.8x
- EV / EBITDA
- 18.5x
- Debt / equity
- —
- Employees
- 57,000
ABBV report card
BTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth10.2%B
- Gross margin72.8%A
- Operating margin40.0%A
- FCF margin28.3%A
- Return on equity——
- Net debt / EBITDA2.1xD
- Forward P/E17.6xB
- PEG ratio0.5xA
- Shareholder yield2.6%C
- Share count change / yr1.2%D
AbbVie financials
Revenue went from $25.6B in fiscal 2016 to $61.2B in fiscal 2025, growing 10.1% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6B | $28.2B | $32.8B | $33.3B | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Gross profit | $19.8B | $21.2B | $25.0B | $25.8B | $30.4B | $38.8B | $40.6B | $33.9B | $39.4B | $43.0B |
| Operating income | $9.3B | $9.5B | $6.4B | $13.0B | $11.4B | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $6.0B | $5.3B | $5.7B | $7.9B | $4.6B | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| EPS (diluted) | $3.63 | $3.30 | $3.66 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Free cash flow | — | $9.4B | $12.8B | $12.8B | $16.8B | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Buybacks | $6.0B | $1.4B | $12.0B | $629.0M | $978.0M | $934.0M | $1.5B | $2.0B | $1.7B | $980.0M |
| Dividends paid | $3.7B | $4.1B | $5.6B | $6.4B | $7.7B | $9.3B | $10.0B | $10.5B | $11.0B | $11.7B |
| Diluted shares | 1.6B | 1.6B | 1.5B | 1.5B | 1.7B | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into ABBV?
A reverse DCF asks what growth the current price requires. With an enterprise value of $569.1B and $18.2B of trailing free cash flow, AbbVie needs to grow free cash flow about 22.0% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 1.2% a year over the last five years.
P/E ratio history
Current 121.0x vs. median 23.9x (10th–90th percentile 16.9x–80.4x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
ABBV dividend
- Dividend yield
- 2.42%
- Annual dividend
- $6.92
- Years of increases
- 12
- 5-yr dividend growth
- 6.8%
- per year
- Payout ratio
- 190%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
ABBV earnings
Next report: October 30, 2026. AbbVie has beaten EPS estimates 1 quarters in a row. Last quarter's revenue was $17.0B (+10% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 31, 2026 | $3.61 | $3.65 | +1.1% |
| Apr 29, 2026 | $2.67 | $2.65 | -0.8% |
| Feb 4, 2026 | $2.65 | $2.71 | +2.2% |
| Oct 31, 2025 | $1.78 | $1.86 | +4.2% |
| Jul 31, 2025 | $2.91 | $2.97 | +2.1% |
| Apr 25, 2025 | $2.40 | $2.46 | +2.6% |
| Jan 31, 2025 | $2.12 | $2.16 | +1.9% |
| Oct 30, 2024 | $2.92 | $3.00 | +2.8% |
Stocks like ABBV
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 AMGN Amgen | -1.79% | +54% | $237.5B | 27.3x | Compare |
 GILD Gilead Sciences | -0.73% | +32% | $193.5B | — | Compare |
 VRTX Vertex Pharmaceuticals Incorpor | -2.10% | +24% | $132.8B | 29.9x | Compare |
 REGN Regeneron Pharmaceuticals | -1.72% | +41% | $82.9B | 19.9x | Compare |
 MRNA Moderna | -1.25% | +662% | $79.9B | — | Compare |
 BIIB Biogen | -1.24% | +67% | $37.0B | 44.5x | Compare |
 INCY Incyte | -1.04% | +30% | $23.5B | 14.7x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
ABBV news
- AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales · Oct 24, 2026
- AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases · Oct 24, 2026
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease · Oct 23, 2026
- AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? · Oct 23, 2026
- Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market · Oct 23, 2026
ABBV stock FAQ
What is ABBV's market cap?
AbbVie's market capitalization is $504.76 billion as of October 23, 2026, ranking 20th in the S&P 500.
What is ABBV's P/E ratio?
ABBV trades at a trailing price-to-earnings ratio of 80.7x and a forward P/E of 17.6x. Its median P/E over the period we track is 23.9x.
Does ABBV pay a dividend?
Yes. AbbVie pays $6.92 per share a year, a 2.42% yield. It has raised its dividend 12 years in a row. Dividends grew 6.8% a year over the last five years.
How much has ABBV stock returned?
Including reinvested dividends, ABBV returned +28.9% over one year, +25.6% a year over five years, +21.6% a year over ten years through October 23, 2026.
Is ABBV stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies AbbVie must grow free cash flow about 22% a year for the next decade. Its free cash flow grew 1% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
When does ABBV report earnings?
AbbVie is expected to report earnings on October 30, 2026. It has beaten EPS estimates 1 quarters in a row.
How many employees does AbbVie have?
AbbVie has about 57,000 full-time employees, or $1.1 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology